The story of Causaly, a member of the Scale Up 3rd Batch, began when Yiannis and his co-founder Artur, both computer scientists and passionate readers, envisioned a way to teach a computer to read at superhuman speed. They set their sights on the biomedical domain, a field rich with millions of publications containing critical insights for advancing human health. This ambitious vision culminated in the development of an AI-driven platform capable of rapidly analyzing vast amounts of data, distilling weeks of research into a matter of minutes. At Causaly, the goal is to provide high-precision search capabilities to make navigating scientific literature more efficient and increase  research productivity by up to 90%. 

Their impact is far-reaching, with industry giants like Gilead and Novo Nordisk, as well as regulatory bodies like the FDA, relying on Causaly for scientific exploration. The company collaborates with major players in the pharmaceutical industry, including giants like Gilead, Novo Nordisk, and regulatory agencies such as the FDA. They are also trusted by 12 of the world’s 20 largest pharmaceutical giants and lie at the forefront of life-saving research.

Causaly raised $60 million in Series B funding led by ICONIQ Growth and with participation from returning investors including Index Ventures, Marathon Venture Capital, and more. With this new capital, the platform is extending their product lead and expanding commercial relationships. 

Causaly in Three:

What problem is Causaly solving? Causaly tackles the overwhelming challenge of analyzing vast biomedical data to support life-saving drug discovery and development, enabling researchers to extract insights faster than ever before.

What’s innovative about Causaly? Causaly’s platform combines a sophisticated knowledge graph with generative AI to read and analyze biomedical literature at superhuman speeds. This approach accelerates drug discovery, transforming weeks of data analysis into mere minutes.

Who can use Causaly? Causaly is designed for pharmaceutical companies, biomedical researchers, and regulatory bodies who need to quickly access and make sense of extensive biomedical data for drug development and research purposes.

Causaly is co-founded by Yiannis Kiachopoulos and Artur Saudabayev who have cumulative, in-depth, international experience across consulting, computer science and natural language processing, truly understanding multiple dimensions of what it takes to build a strong company and product. It is no luck that the company is growing rapidly and is trusted by top investors and companies world-wide. With over 80 million unique interactions between entities on the platform, Causaly shows great promise for the future.